Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit

Table 2 Intraoperative, postoperative, and follow-up data of patients undergoing curative surgery

Patient	Surgery	Operation time (min)	Blood loss (mL)	Complication (CD)	Postoperative tumor marker (1 month)	Postoperative hospital stay (days)	Adjuvant therapy	Disease-free time (months)	Survival time (months)
1	ELL + I + T	825	1850	IIIa	N/A	30	RT	3	6
2	RL + I + T	725	630	I	AFP 175.5 ng/dL	10	Thalidomide	5	9
3	RL + I + T	721	850	IIIb	AFP 188.5 ng/dL	29	Thalidomide	12	15
4	A + ERL + I + T	602	3900	IIIa	N/A	13	CT	15	17
5	ERL + D + T	402	500	I	AFP 218 ng/dL	10	Thalidomide	8	14
6	RL + T	350	1000	Nil	AFP 450 ng/dL	12	Thalidomide	9	17
7	ERL + T	377	900	I	AFP 500 ng/dL	10	Thalidomide	5	15
8	RL + T	302	1200	Nil	AFP 12.7 ng/dL	8	Sorafenib	39+	Alive
9	ELL + T	328	920	II	AFP <0.5 ng/dL	15	Sorafenib	30+	Alive
10	RL + T	312	700	Nil	AFP 5.27 ng/dL	9	Sorafenib	10+	Alive
Mean		494.4	1245			14.6
SD		201.8	1004.9			8.1

ELL extended left lobectomy, I IVC resection, T thrombectomy, A adrenectomy, D partial diaphragm resection, RL right lobectomy, ERL extended right lobectomy, CD Clavien-Dindo classification, N/A no analysis, RT radiotherapy, CT chemotherapy, + the duration to date of article submission

ISSN: 1477-7819